PriceTargets.com logo

Ikena Oncology - IKNA Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $3.00
  • Forecasted Upside: 85.19%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.62 As of 12/17/2024 01:00 AM ET
▲ +0.01 (0.62%)

This chart shows the closing price for IKNA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ikena Oncology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IKNA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IKNA

Analyst Price Target is $3.00
▲ +85.19% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Ikena Oncology in the last 3 months. The average price target is $3.00, with a high forecast of $4.00 and a low forecast of $2.00. The average price target represents a 85.19% upside from the last price of $1.62.

This chart shows the closing price for IKNA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 2 polled investment analysts is to moderate buy stock in Ikena Oncology. This rating has held steady since May 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/25/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/18/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/11/2024HC WainwrightReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
11/7/2024WedbushReiterated RatingNeutral$2.00
8/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
5/29/2024WedbushDowngradeOutperform ➝ Neutral$8.00 ➝ $2.00
5/29/2024HC WainwrightLower TargetBuy ➝ Buy$11.00 ➝ $4.00
5/14/2024WedbushReiterated RatingOutperform ➝ Outperform$8.00
3/19/2024HC WainwrightReiterated RatingBuy ➝ Buy$11.00
3/12/2024WedbushReiterated RatingOutperform$8.00
1/19/2024WedbushReiterated RatingOutperform ➝ Outperform$8.00
1/19/2024HC WainwrightReiterated RatingBuy ➝ Buy$11.00
11/16/2023William BlairReiterated RatingOutperform
11/9/2023HC WainwrightLower TargetBuy ➝ Buy$18.00 ➝ $11.00
9/21/2023WedbushInitiated CoverageOutperform$11.00
8/7/2023HC WainwrightReiterated RatingBuy ➝ Buy$18.00
5/4/2023HC WainwrightReiterated RatingBuy$18.00
3/17/2023HC WainwrightReiterated RatingBuy$22.00
3/15/2023Credit Suisse GroupLower TargetOutperform$16.00 ➝ $13.00
11/29/2022Credit Suisse GroupLower TargetOutperform$18.00 ➝ $16.00
11/29/2022HC WainwrightLower TargetBuy$26.00 ➝ $22.00
11/8/2022Credit Suisse GroupLower TargetOutperform$20.00 ➝ $18.00
4/13/2022HC WainwrightBoost TargetBuy$25.00 ➝ $26.00
3/17/2022Credit Suisse GroupLower Target$27.00 ➝ $24.00
12/23/2021HC WainwrightInitiated CoverageBuy$25.00
8/13/2021Credit Suisse GroupLower TargetOutperform$30.00 ➝ $27.00
7/2/2021CowenReiterated RatingBuy
4/20/2021William BlairInitiated CoverageOutperform
4/20/2021Jefferies Financial GroupInitiated CoverageBuy
4/20/2021Credit Suisse GroupInitiated CoverageOutperform$30.00
(Data available from 12/18/2019 forward)

News Sentiment Rating

1.93 (Strong Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/22/2024
  • 3 very positive mentions
  • 5 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2024
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2024

Current Sentiment

  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

Ikena Oncology logo
Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $1.62
Low: $1.54
High: $1.63

50 Day Range

MA: $1.70
Low: $1.61
High: $1.76

52 Week Range

Now: $1.62
Low: $1.22
High: $2.32

Volume

239,869 shs

Average Volume

231,152 shs

Market Capitalization

$78.18 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.49

Frequently Asked Questions

What sell-side analysts currently cover shares of Ikena Oncology?

The following equities research analysts have issued stock ratings on Ikena Oncology in the last year: HC Wainwright, and Wedbush.
View the latest analyst ratings for IKNA.

What is the current price target for Ikena Oncology?

0 Wall Street analysts have set twelve-month price targets for Ikena Oncology in the last year. Their average twelve-month price target is $3.00, suggesting a possible upside of 85.2%. HC Wainwright has the highest price target set, predicting IKNA will reach $4.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $2.00 for Ikena Oncology in the next year.
View the latest price targets for IKNA.

What is the current consensus analyst rating for Ikena Oncology?

Ikena Oncology currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for IKNA.

What other companies compete with Ikena Oncology?

Other companies that are similar to Ikena Oncology include Valneva, Larimar Therapeutics, Foghorn Therapeutics, C4 Therapeutics and Immutep. Learn More about companies similar to Ikena Oncology.

How do I contact Ikena Oncology's investor relations team?

Ikena Oncology's physical mailing address is 645 SUMMER STREET SUITE 101, BOSTON MA, 02210. The company's listed phone number is 857-273-8343 and its investor relations email address is [email protected]. The official website for Ikena Oncology is ikenaoncology.com. Learn More about contacing Ikena Oncology investor relations.